Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATAI Life Sciences B.V.*

1.48
+0.09006.47%
Post-market: 1.500.0200+1.35%19:56 EDT
Volume:1.44M
Turnover:2.12M
Market Cap:287.12M
PE:-1.86
High:1.52
Open:1.42
Low:1.42
Close:1.39
Loading ...

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

GlobeNewswire
·
11 Mar

Atai Life Sciences completes enrollment of Phase 2b trial of BPL-003

TIPRANKS
·
05 Mar

atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

GlobeNewswire
·
05 Mar

Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey
·
02 Mar

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
25 Feb

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

GlobeNewswire
·
20 Feb

ATAI Life Sciences Announces Public Offering Pricing

TIPRANKS
·
14 Feb

ATAI Life Sciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb

Atai Life Sciences Prices $55 Million Stock Offering

MT Newswires Live
·
13 Feb

atai Life Sciences Says Pricing Of Registered Underwritten Offering Of 26.1 Million Common Shares At $2.10 Per Share

Reuters
·
13 Feb

Atai Life Sciences Announces Proposed Public Offering Of Common Shares

Reuters
·
13 Feb

atai Life Sciences Announces Proposed Public Offering of Common Shares

GlobeNewswire
·
13 Feb

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Dow Jones
·
05 Feb

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive
·
03 Feb

Atai Life Sciences And 2 Other Promising Penny Stocks On US Exchanges

Simply Wall St.
·
31 Jan